Big Pharma CEOs Suggest Policy Changes As They Return To Beijing
Also, Astellas Employee Detained
Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.
You may also be interested in...
China Micron Ban Not Cause For Further Health Sector Worry?
China has taken a new counterstrike against the US in the chips sector, but the risk of potential wider impact on the biopharma sector appears to be limited given other tighter regulations already in place.
'Being Innovative Not Enough': Multinationals Want Driver‘s Seat In Changing China
Multinational pharma firms are exploring their next growth trajectories in China, where some including AstraZeneca and Roche are deepening their commitment by becoming further integrated into local innovation ecosystems and pursuing deals, while others such as Pfizer are focusing on tackling reimbursement challenges.
Chinese Language Podcast: 重磅交易, 亚太药企如何度过资本寒冬, 减肥药风口
The latest China biopharma trends, including recent multimillion dollar deals by biotech firms, companies preparing for the worst as the 'capital winter' lingers, and GLP-1 agents for obesity are discussed by Brian Yang in Beijing and Dexter Yan in Shanghai in this latest Chinese-language podcast.